NYCC’s Frank J. Nicchi Earns NYSCA’s Highest Award at Homecoming Ceremony
Written by TAC Staff   
Sunday, 25 September 2011 21:15

awardfranknyccSeneca Falls:  New York State Chiropractic Association past-president Dr. Mariangela Penna presented NYCC President Dr. Frank J. Nicchi with the association’s highest honor, the Ernest G. Napolitano Award, during the College’s Homecoming weekend attended by more than 430 alumni, students and members of the faculty.

Homecoming speakers included Texas Chiropractic College faculty member Dr. Michael Dobbins, popular guest lecturer Dr. Mark Charrette, NYCC faculty members Drs. Teresa Hoban, Sandra Hartwell, and Lisa Bloom, Academy of Chiropractic Orthopedics board member Dr. Stephen Savoie, SpiderTech, Inc.’s Dr. Nick Tsaggarelis, and Zheng Gu Tui Na’s co-founder Frank Butler, LAc.

A Friday evening dinner dance at nearby Ventosa Vineyards drew more than 230 people who observed NYCC Board of Trustees’ recognition of Drs. George and Teresa Ngo (NYCC ’72) for their many years of generous support to both the College and to the chiropractic profession. The Ngos number among a select group comprising NYCC’s President’s Council charter members. A wine and cheese reception and Casino Night rounded out the weekend on Saturday evening.

College sponsors and vendors who helped make the event a resounding success included Standard Process, Inc., Foot Levelers, Inc., Future Health, Inc., Performance Health, Multi Radiance, Douglas Laboratories, and NCMIC.

Multaq (dronedarone): Increased Risk of Death or Serious Cardiovascular Events
Written by TAC Staff   
Tuesday, 23 August 2011 21:41

medwatchFDA notified healthcare professionals that it is reviewing data from a clinical trial that evaluated the effects of the antiarrhythmic drug Multaq (dronedarone) in patients with permanent atrial fibrillation. The study was stopped early after the data monitoring committee found a two-fold increase in death, as well as two-fold increases in stroke and hospitalization for heart failure in patients receiving Multaq compared to patients taking a placebo. FDA is evaluating whether and how the preliminary results of the PALLAS study apply to patients taking Multaq for paroxysmal or persistent atrial fibrillation or atrial flutter. The PALLAS study results are considered preliminary at this time.

Multaq is approved for use to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted.

At this time, patients taking Multaq should talk to their healthcare professional about whether they should continue to take Multaq for non-permanent atrial fibrillation. Patients should not stop taking Multaq without talking to a healthcare professional. Healthcare professionals should not prescribe Multaq to patients with permanent atrial fibrillation.

Source: FDA

Valproate Products: Risk of Impaired Cognitive Development in Children Exposed In Utero
Written by TAC Staff   
Tuesday, 23 August 2011 21:35

pregnantIncluding valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics

The FDA notified healthcare professionals that children born to mothers who take the anti-seizure medication valproate sodium or related products (valproic acid and divalproex sodium) during pregnancy have an increased risk of lower cognitive test scores than children exposed to other anti-seizure medications during pregnancy. This conclusion is based on the results of epidemiologic studies that show that children born to mothers who took valproate sodium or related products throughout their pregnancy tend to score lower on cognitive tests (IQ and other tests) than children born to mothers who took other anti-seizure medications during pregnancy. See the Drug Safety Communication for a data summary and additional information.

Valproate products are FDA-approved drugs to treat seizures, and manic or mixed episodes associated with bipolar disorder (manic-depressive disorder), and to prevent migraine headaches. They are also used off-label (for unapproved uses) for other conditions, particularly for other psychiatric conditions.

Healthcare professionals should inform women of childbearing age of the increased risk for adverse effects on cognitive development with prenatal valproate exposure, and should continue to counsel women of childbearing potential taking valproate about the increased risk of major malformations, including neural tube defects, when valproate is used during pregnancy.

Source: FDA

Las Vegas chiropractor sentenced in Social Security fraud case
Written by TAC Staff   
Tuesday, 19 July 2011 20:44


A Las Vegas chiropractor and boxing judge was sentenced Monday to 18 months in prison for fraudulently collecting $400,000 in Social Security disability benefits.

The sentence handed down to Paul G. Smith, 66, includes three years of supervised release and $435,674 in restitution.

According to a news release from the U.S. Department of Justice:

■ Smith received Social Security disability benefits from September 1994 to December 2005 based on his claim that a back injury affected his ability to work as a chiropractor.

■ While receiving the benefits, Smith continued to regularly own and manage Las Vegas chiropractic business Rainbow Chiropractic Center, regularly withdrawing revenues for personal expenses. Smith sold the business for $325,000 in December 2002.

■ He also worked as a licensed boxing judge in Nevada on a consistent and ongoing basis from January 1987 until December 2007, judging about 189 fights and receiving $133,000 in income. Smith failed to provide information about his employment to the Social Security Administration.

Smith pleaded guilty to Social Security fraud on Aug. 26 and must report to prison by July 20.

Sourse: Las Vegas Review-Journal

Connecticut Chiropractors Victorious in 2 suits over VOCA
Written by TAC Staff   
Tuesday, 19 July 2011 20:41


Connecticut chiropractors, under fire for allegedly violating state law and failing to warn patients of the potential risk of some of their treatments, scored two recent victories, thanks to the General Assembly and the courts.

“We’re very pleased with the outcome in the legislative arena as well as the courts,” said Dr. Gina Carucci, president of the Connecticut Chiropractic Association.

The legislative victory centers on Connecticut’s use-of-name statute, which mandates that “No person shall practice as a chiropractor under any name other than the name of the chiropractor actually owning the practice or a corporate name containing the name or names of such chiropractors.” A bill just passed by the General Assembly eliminates that requirement while still mandating that licensed chiropractors display their names at the entrance to their business. The bill also grants amnesty to chiropractors found in violation of the use-of-name law.

In action now made moot by the new legislation, Victims of Chiropractic Abuse (VOCA) had identified close to 500 chiropractors that it claimed were in violation of the use-of-name statute.

The second victory for chiropractors involves a lawsuit filed by VOCA against two chiropractic associations, the Connecticut Chiropractic Association and the Connecticut Chiropractic Council. The lawsuit, filed a year ago, charges, in part, that chiropractors don’t adequately inform patients about the risks associated with certain neck adjustments.

Earlier this month a Superior Court judge found that VOCA lacked standing to file the suit and dismissed the case. Levy said VOCA is reviewing its legal options. “We remain steadfast in our commitment to pursing informed consent for health care consumers so that they can make fully informed decisions,” she said.

Source: The New Haven Independant


Page 5 of 8
TAC Cover
TCA Cover
BL Cover
Buyers Guide

Click on image above
to view the
Digital Edition






TAC Publications

The American Chiropractor Magazine: Digital Issues | Past Issues | Buyer's Guide


More Information

TAC Editorial: About | Circulation | Contact

Sales: Advertising | Subscriptions | Media Kit